Business Wire

WELLO2

18.5.2020 07:02:06 CEST | Business Wire | Press release

Share
WellO2: Counter Pressure Steam Breathing Helps With Voice Symptoms

Training with a counter pressure steam breathing device has the potential to improve voice quality, as revealed in a recent pilot study in Finland. A report on the study was published in Journal of Voice, a peer-reviewed publication regarded as the world's premiere journal for voice medicine and research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005004/en/

The protocol of another study, now investigating benefits of using WellO2, a unique counter pressure steam breathing device, with patients with chronic obstructive pulmonary symptoms, has been approved by the ethical committee of the University of Tampere. Both studies focus on the effects of the combination of the inspiratory and expiratory muscle training with warm steam.

Voice professionals have found help

Even before the Finnish study came out, various renown voice professionals have been using WellO2 to help with their voice problems. Among the artists is Uriah Heep’s lead singer Bernie Shaw , who has warmly endorsed WellO2 (see link, below).

The aim of the Finnish pilot study was to determine the efficacy of the 4-week breathing exercise intervention on participants with voice symptoms. Six non-smoking women, mean age 49, experiencing voice symptoms made respiratory muscle exercises for a month with counter pressure on both inspiration and expiration and with warm steam. Speech samples were acoustically measured and perceptually analyzed using the GRBAS, the grade, roughness, breathiness, asthenia and strain scale. Afterwards, perceived voice symptoms and self-reported effort in breathing and phonation were analyzed.

Participants: Breathing was significantly less effortful

The total score of the Acoustic Voice Quality Index (AVQI) and some of its subcomponents, namely shimmer and harmonic-to-noise ratio, and the perceptually evaluated grade, roughness, and strain indicated significantly improved voice quality. However, neither the nature or frequency of the experienced voice symptoms nor the perceived phonatory effort changed as the function of intervention. According to the participants, their breathing was significantly less effortful after the intervention, although no significant changes were observed in the objective respiratory measurements with a spirometer.

According to the study, training with the WellO2 device has the potential to improve voice quality. However, the effects of using WellO2 need to be confirmed by further studies with a larger number of participants, the pilot study concluded.

New studies with WellO2 and chronic obstructive pulmonary symptoms

The ethical committee of the University of Tampere recently gave a positive statement for the clinical study of WellO2 with patients with chronic obstructive pulmonary symptoms. The team is testing the effect of WellO2 device for the respiratory muscle exercises that provides counter pressure. There are several hundreds of referred studies on steam inhalation and counter pressure breathing. None have found any severe side effects for using such devices.

Patented WellO2 counter pressure steam breathing device was developed by Hapella Oy, Finland. The device has been available since 2016 as a non-medical device. Over 35 000 devices have been sold in Finland, alone. It is sold both in pharmacies and other stores, like electric commodity store chain of Elgiganten in Sweden and Elkjøp in Norway. Wello2 is available on e-commerce, also at various Amazon e-stores, e.g. in Italy and Germany.

Medical references & links:
https://wello2.com/blogs/news/wello2-counter-pressure-steam-breathing-helps-with-voice-symptoms

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye